Clovis Oncology Inc (NASDAQ:CLVS) reported financial results for its quarter and year ended December 31, 2015, and provided an update on the Company’s clinical development programs and regulatory outlook for 2016.

“2016 has the potential to be a very transformational year for Clovis,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “We are preparing for the rociletinib ODAC panel in April ahead of our June 28, 2016 PDUFA date, as well as the planned NDA submission of rucaparib during the second quarter. Our U.S. commercial and medical affairs organizations are in place as we work toward the potential launch of two oncology drugs in the U.S. within the next twelve months.”

2015 Financial Results

Clovis had $528.6 million in cash, cash equivalents and available-for-sale securities as of December 31, 2015. Cash used in operating activities was $75.7 million for the fourth quarter of 2015, and $253.1 million for the year ending December 31, 2015, inclusive of $12.0 million in rociletinib milestone payments made in the third quarter of 2015.

Clovis reported a net loss for the fourth quarter of 2015 of $119.5 million ($3.12) per share, and $352.9 million ($9.79) per share for the year ended December 31, 2015. Importantly, the net loss for the fourth quarter and full year 2015 includes a $89.6 million non-cash charge ($61.0 million net of the related income tax benefit) for the impairment of the intangible asset relating to the lucitanib product rights recorded in 2013 in connection with the Company’s acquisition of Ethical Oncology Science S.p.A. (EOS) and a$26.9 million non-cash expense credit for the reduction in the fair value of the contingent purchase considerations liability, also related to the EOS acquisition. The adjusted net loss excluding these items was $85.4 million ($2.23 per share) in the fourth quarter of 2015 and $318.8 million ($8.85 per share) for the year ended December 31, 2015. The net loss for the fourth quarter of 2014 was $54.9 million ($1.62 per share) and $160.0 million ($4.72 per share) for the year ended December 31, 2014.

Research and development expenses totaled $76.0 million for the fourth quarter of 2015 and $269.3 million for the full year 2015, compared to $50.1 million for the fourth quarter and $137.7 million for the full year 2014. The increase in expenses for both periods is due to the significantly expanded clinical development activities for rociletinib and rucaparib, increased commercial product planning costs associated with the potential approval and launch of rociletinib, and increased personnel-related expenses associated with the hiring of additional staff to support the Company’s expanded activities, including the hiring of the U.S. commercial and medical affairs organizations.

General and administrative expenses totaled $8.2 million for the fourth quarter of 2015 and $30.5 million for the full year 2015, compared to $5.6 million for the fourth quarter and $21.5 million for the full year 2014. The increase year over year is primarily due to personnel costs for employees engaged in general and administrative activities, increased facility costs and higher professional service fees.

As noted above, in the fourth quarter of 2015 Clovis recorded a non-cash impairment charge of $89.6 million to reflect a reduction in the estimated fair value of the intangible asset related to lucitanib. This reduction in fair value was the result of our and our development partner’s decision to terminate the development of lucitanib for lung cancer, as well as updates to the probability-weighted discounted cash flow assumptions for the breast cancer indication.

In connection with its acquisition of EOS, Clovis is obligated to pay additional consideration to the former EOS shareholders if certain future regulatory and sales milestones for lucitanib are achieved. The estimated fair value of these contingent payments is recorded as a liability on the Company’s balance sheet. During the fourth quarter of 2015, Clovis recorded a $26.9 millionreduction in the fair value of the contingent consideration liability due to a change in the estimated probability-weighted future milestone payments. This reduction is included as a non-cash credit to operating expenses in Clovis’ 2015 results of operations.

There was no acquired in-process research and development expense for the fourth quarter of 2015, and $12.0 million for the full year 2015, with none reported in the fourth quarter of 2014 and $8.8 million for the full year 2014. During the third quarter of 2015, the Company made milestone payments totaling $12.0 million upon the acceptance of the NDA and MAA submissions for rociletinib by the U.S. FDA and European Medicines Agency, respectively. In the first quarter of 2014, the Company recorded milestone revenue of $13.6 million received pursuant to our collaboration and license agreement for lucitanib and also recognized charges for acquired in-process research and development expense totaling $8.4 million associated with milestone payments incurred for rociletinib and lucitanib.

Operating expenses for the fourth quarter of 2015 and year ended December 31, 2015 include share-based compensation expense totaling $10.9 million and $40.4 million, respectively.

2016 Key Milestones and Objectives

Highlights of planned or completed objectives for each product follow:

Rociletinib

Rociletinib is an investigational therapy for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation. The U.S. Food and Drug Administration (FDA) has accepted Clovis’ New Drug Application (NDA) for rociletinib and has granted it priority review status with a Prescription Drug User Fee Act (PDUFA) action date of June 28, 2016. In addition, theEuropean Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for rociletinib. Both reviews are ongoing.

The Company is preparing for its scheduled Oncologic Drugs Advisory Committee (ODAC) panel discussion regarding the rociletinib NDA on April 12, 2016.

During the first quarter the Company initiated a Phase 1b/2 trial of rociletinib in combination with investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PD-L1 antibody). The Clovis-sponsored study is designed to assess the safety and activity of the combination in patients with activating EGFR mutation-positive (EGFRm) advanced or metastatic NSCLC.

Rucaparib

During the second quarter of 2016, Clovis intends to complete its rolling NDA submission to the FDA for rucaparib as treatment for advanced ovarian cancer patients with a tumor BRCA mutation (germline and somatic mutations), including platinum-sensitive, -resistant and -refractory patients. In addition, the Company intends to submit an MAA for rucaparib for a comparable ovarian treatment indication by the end of 2016. Enrollment in the ARIEL3 pivotal maintenance study is expected to complete in the next few months, with data expected to be available approximately 12 months later. Pending positive data, supplemental NDAs for maintenance indications in tumor BRCA mutant patients and BRCA-like patients with advanced ovarian cancer are expected to follow.

During the second half of 2016, the Company intends to initiate a study of rucaparib in metastatic castrate-resistant BRCA mutant (inclusive of germline and somatic) prostate cancer patients. In addition, the Company expects to initiate the ARIEL4 confirmatory study in advanced ovarian cancer, including both tumor BRCA mutant and, potentially, BRCA-like patients.

Lucitanib

A Phase 2 program is ongoing to explore lucitanib in patients with treatment-refractory breast cancer. In parallel with Clovis’ sponsored study, a Servier-sponsored Phase 2 study of lucitanib in patients with advanced breast cancer is underway to identify the population of patients most likely to benefit from lucitanib therapy. (Original Source)

Shares of Clovis Oncology closed today at $17.29, down $0.79 or -4.37%. CLVS has a 1-year high of $116.75 and a 1-year low of $17.07. The stock’s 50-day moving average is $21.61 and its 200-day moving average is $59.71.

On the ratings front, Clovis has been the subject of a number of recent research reports. In a report issued on January 25, Mizuho analyst Eric Criscuolo reiterated a Hold rating on CLVS, with a price target of $23, which implies an upside of 26.1% from current levels. Separately, on January 20, Credit Suisse’s Kennen MacKay initiated coverage with a Buy rating on the stock and has a price target of $32.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Eric Criscuolo and Kennen MacKay have a total average return of -15.4% and -13.8% respectively. Criscuolo has a success rate of 25.0% and is ranked #3310 out of 3666 analysts, while MacKay has a success rate of 15.4% and is ranked #3194.

Clovis Oncology Inc is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets.